Disease · MONDO_0020311
Comparisons in its trials37
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 37
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Sabatolimab (MBG453) + Azacitidine vs Placebo + Azacitidine: deaths from any cause | 161 of 265 | 160 of 265 | 530 | NCT04266301 | Trial comparisons |
| Sabatolimab (MBG453) + Azacitidine vs Placebo + Azacitidine: serious adverse events | 174 of 263 | 164 of 265 | 528 | NCT04266301 | Trial comparisons |
| Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2: Number of Participants With at Least 1 Inpatient Hospital Admissions Related to HR MDS, CMML or Low-blast AML | 3 of 227 | 9 of 227 | 454 | NCT03268954 | Trial comparisons |
| Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2: Sixty-Day Mortality Reported as Number of Participants Who Died Up to Day 60 | 15 of 220 | 14 of 223 | 443 | NCT03268954 | Trial comparisons |
| Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2: Thirty-Day Mortality Reported as Number of Participants Who Died Up to Day 30 | 6 of 220 | 5 of 223 | 443 | NCT03268954 | Trial comparisons |
| Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2: deaths from any cause | 153 of 220 | 150 of 223 | 443 | NCT03268954 | Trial comparisons |
| Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2: serious adverse events | 145 of 220 | 156 of 223 | 443 | NCT03268954 | Trial comparisons |
| Guadecitabine vs Treatment Choice: deaths from any cause | 237 of 277 | 122 of 140 | 417 | NCT02907359 | Trial comparisons |
| Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2: Number of Participants With CR and Marrow CR, PR and Hematologic Improvement (HI) | 112 of 206 | 117 of 208 | 414 | NCT03268954 | Trial comparisons |
| Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2: Number of Participants With Overall Response 2 (OR2) | 94 of 206 | 94 of 208 | 414 | NCT03268954 | Trial comparisons |
| Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2: Number of Participants With CR and Marrow CR and PR | 91 of 206 | 87 of 208 | 414 | NCT03268954 | Trial comparisons |
| Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2: Number of Participants With CR, Partial Remission (PR) and Hematologic Improvement (HI) | 77 of 206 | 76 of 208 | 414 | NCT03268954 | Trial comparisons |
| Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2: Number of Participants With CR and Marrow CR | 91 of 206 | 87 of 208 | 414 | NCT03268954 | Trial comparisons |
| Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2: Number of Participants With Complete Remission (CR) and CR+ Complete Remission With Incomplete Blood Count Recovery (CRi) | 71 of 206 | 63 of 208 | 414 | NCT03268954 | Trial comparisons |
| Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2: Number of Participants With Overall Response (OR) | 73 of 206 | 64 of 208 | 414 | NCT03268954 | Trial comparisons |
| Guadecitabine vs Treatment Choice: serious adverse events | 216 of 270 | 65 of 122 | 392 | NCT02907359 | Trial comparisons |
| Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2: Number of Participants With Hematologic Improvement (HI) | 76 of 157 | 70 of 163 | 320 | NCT03268954 | Trial comparisons |
| MDS or CMML: IV Decitabine vs MDS or CMML: ASTX727: MDS/CMML: Number of Participants With Grade 3 or Higher TEAEs | 89 of 132 | 121 of 130 | 262 | NCT03306264 | Trial comparisons |
| MDS or CMML: IV Decitabine vs MDS or CMML: ASTX727: MDS/CMML: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 127 of 132 | 130 of 130 | 262 | NCT03306264 | Trial comparisons |
| Sabatolimab (MBG453) + Azacitidine vs Placebo + Azacitidine: Number of Participants Who Become Red Blood Cells (RBC) Transfusion Independent After Randomization | 50 of 96 | 53 of 108 | 204 | NCT04266301 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0020311/comparisons